Add Yahoo as a preferred source to see more of our stories on Google. The FDA has approved a label change to Pfizer's contraceptive injection The US Food and Drug Administration (FDA) has approved a ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Hosted on MSN
Pfizer succeeds in late-stage trial for Tukysa breast cancer drug as maintenance therapy
Pfizer (NYSE:PFE) on Tuesday announced that a Phase 3 trial designed to test its FDA-approved antitumor agent Tukysa as a first-line maintenance therapy in breast cancer reached its main goal with a ...
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
The U.S. Food and Drug Administration (FDA) has approved a major safety update to the label of Depo-Provera, a widely used birth control injection. Nearly 2,000 women have filed lawsuits against ...
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...
(RTTNews) - Pfizer Inc. (PFE) and Astellas Pharma Inc. (ALPMY, 4503.T) announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (enfortumab vedotin-ejfv), a Nectin-4 directed ...
This trial tested a new treatment for patients with a type of breast cancer (metastatic breast cancer (MBC)) that is positive for HER2, which means the cancer cells have a specific protein that helps ...
The US Food and Drug Administration (FDA) has approved a label change to Pfizer’s injectable contraceptive, Depo-Provera (medroxyprogesterone acetate), which will warn users of their increased risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback